Contrast developer Bracco Diagnostics announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for two contrast agents to be used in CT of the abdomen.
Readi-Cat 2 and Readi-Cat 2 smoothie (barium sulfate) oral suspension will be used in CT scans to delineate the gastrointestinal (GI) tract in adult and pediatric patients. This is the second regulatory approval of a barium-based contrast agent in the U.S. and the first for use in CT, according to Bracco.
Readi-Cat 2 is supplied in 450-mL bottles. Readi-Cat 2 smoothies are available for use by adult and pediatric patients in berry, banana, creamy vanilla, and mochaccino flavors, also in 450-mL bottles.
